Jutel M, Akdis M, Blaser K, Akdis C A
Department of Internal Medicine and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Allergy. 2006 Jul;61(7):796-807. doi: 10.1111/j.1398-9995.2006.01175.x.
Specific immune suppression and induction of tolerance are essential processes in the regulation and circumvention of immune defence. The balance between allergen-specific T-regulatory (Treg) cells and T helper 2 cells appears to be decisive in the development of allergic and healthy immune response against allergens. Treg cells consistently represent the dominant subset specific for common environmental allergens in healthy individuals. In contrast, there is a high frequency of allergen-specific T helper 2 cells in allergic individuals. A decrease in interleukin (IL)-4, IL-5 and IL-13 production by allergen-specific CD4+ T cells due to the induction of peripheral T cell tolerance is the most essential step in allergen-specific immunotherapy (SIT). Suppressed proliferative and cytokine responses against the major allergens are induced by multiple suppressor factors, such as cytokines like IL-10 and transforming growth factor (TGF)-beta and cell surface molecules like cytotoxic T lymphocyte antigen-4, programmed death-1 and histamine receptor 2. There is considerable rationale for targeting T cells to increase efficacy of SIT. Such novel approaches include the use of modified allergens produced using recombinant DNA technology and adjuvants or additional drugs, which may increase the generation of allergen-specific peripheral tolerance. By the application of the recent knowledge in Treg cells and related mechanisms of peripheral tolerance, more rational and safer approaches are awaiting for the future of prevention and cure of allergic diseases.
特异性免疫抑制和耐受性诱导是免疫防御调节和规避过程中的关键环节。变应原特异性调节性T(Treg)细胞与辅助性T2细胞之间的平衡,似乎在针对变应原的过敏性和健康免疫反应的发展中起决定性作用。在健康个体中,Treg细胞始终是针对常见环境变应原的主要特异性亚群。相比之下,在过敏个体中,变应原特异性辅助性T2细胞的频率较高。通过诱导外周T细胞耐受性,使变应原特异性CD4 + T细胞产生的白细胞介素(IL)-4、IL-5和IL-13减少,是变应原特异性免疫疗法(SIT)中最关键的一步。多种抑制因子可诱导针对主要变应原的增殖和细胞因子反应受到抑制,这些抑制因子包括细胞因子如IL-10和转化生长因子(TGF)-β,以及细胞表面分子如细胞毒性T淋巴细胞抗原-4、程序性死亡-1和组胺受体2。针对T细胞以提高SIT疗效有充分的理论依据。这类新方法包括使用重组DNA技术生产的修饰变应原和佐剂或其他药物,这可能会增加变应原特异性外周耐受性的产生。通过应用关于Treg细胞和外周耐受性相关机制的最新知识,更合理、更安全的方法正等待着用于过敏性疾病的预防和治疗。